LGND241220C105000
- 10.50
- 0.000.00%
Ligand Pharmaceuticals Newsroom
Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $150
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $140
A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $135 to $150
Ligand Pharmaceuticals Analyst Ratings
Ligand Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $150
H.C. Wainwright Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $157
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
H.C. Wainwright Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $157
Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $125
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
Ligand Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Ligand Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $157
Ligand Pharmaceuticals Initiated at Outperform by Oppenheimer
Ligand Pharmaceuticals Analyst Ratings
Oppenheimer Initiates Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $135